

# Seth M Steinberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6357994/seth-m-steinberg-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

272  
papers

10,028  
citations

47  
h-index

95  
g-index

286  
ext. papers

12,224  
ext. citations

5  
avg, IF

5.64  
L-index

#	Paper	IF	Citations
272	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.. <i>Oncologist</i> , <b>2022</b> , 27, e273-e285	5.7	0
271	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.. <i>Oncologist</i> , <b>2022</b> , 27, 198-209	5.7	0
270	The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/- Ipi).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 452-452	2.2	
269	Safety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	4
268	Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas. <i>Blood</i> , <b>2021</b> , 138, 4504-4504	2.2	1
267	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2101405	2.2	7
266	Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation. <i>Blood</i> , <b>2021</b> , 138, 101-101	2.2	2
265	Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. <i>Blood Advances</i> , <b>2021</b> , 5, 5312-5322	7.8	2
264	Characteristics of Matriculants to Thoracic Surgery Residency Training Programs. <i>Annals of Thoracic Surgery</i> , <b>2021</b> , 112, 2070-2075	2.7	3
263	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. <i>Blood Advances</i> , <b>2021</b> , 5, 1660-1670	7.8	9
262	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. <i>Oncologist</i> , <b>2021</b> , 26, 288-e541	5.7	5
261	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , <b>2021</b> , 39, 566-579.e7	24.3	24
260	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS6092-TPS6092	2.2	2
259	Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 507-512	5.3	1
258	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1650-1659	2.2	41
257	Clinical value of FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 787.e17-787.e21	2.8	6
256	Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2

255	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1391-1398	12.9	7
254	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS-mutant pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 821-828	4.3	8
253	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	6
252	Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1584-1592	4.4	
251	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , <b>2021</b> , 26, e847-e858	5.7	9
250	Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 937.e1-937.e7		2
249	Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2934-2939	4.4	1
248	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1678-1685	13.4	1
247	Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells. <i>Blood</i> , <b>2021</b> ,	2.2	13
246	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in Gene. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100231	1.4	1
245	Characterization of Outcomes by Surgical Management of Lung Neuroendocrine Tumors Associated With Cushing Syndrome. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2124739	10.4	0
244	Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100229	1.4	5
243	Reply to K. Takada et al.. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100250	1.4	
242	Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 789078	5.3	0
241	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4268-4279	12.9	59
240	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , <b>2020</b> , 2020, 7935475	3.1	9
239	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2519-2529	2.2	39
238	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , <b>2020</b> , 16, 899-909	3.6	13

237	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 258-267.e1	3.3	6
236	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castlemann disease. <i>Blood</i> , <b>2020</b> , 135, 2316-2319	2.2	16
235	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1430-1442	59.2	163
234	A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies. <i>Oncologist</i> , <b>2020</b> , 25, 532-540	5.7	8
233	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	11
232	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1099-1109	21.7	31
231	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1527-1538	2.2	27
230	Disease-free interval and tumor functional status can be used to select patients for resection/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study. <i>Hpb</i> , <b>2020</b> , 22, 169-175	3.8	3
229	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer <b>2020</b> , 8,		21
228	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1938-1950	2.2	132
227	F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis-The Central Role of Volume. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1570-1575	8.9	1
226	A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2020</b> , 136, 21-21	2.2	
225	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2318-2326	12.9	28
224	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. <i>Blood</i> , <b>2020</b> , 136, 43-45	2.2	6
223	Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 24-25	2.2	4
222	Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival. <i>Blood</i> , <b>2020</b> , 136, 13-14	2.2	14
221	Phase 1b/2 Study of Vopor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	8
220	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11527-11527	2.2	4

219	A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11540-11540	2.2	3
218	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11552-11552	2.2	2
217	Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5039-5039	2.2	2
216	Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 9054-9054	2.2	9
215	Phase II study of nivolumab (anti-PD1), tadalafil, and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4656-TPS4656	2.2	2
214	A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 117-117	2.2	4
213	Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e17569-e17569	2.2	
212	Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5037-5037	2.2	1
211	Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS2572-TPS2572	2.2	
210	Randomized phase II trial of topotecan plus M6620 (VX-970) versus topotecan alone in patients with relapsed small-cell neuroendocrine cancers including small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS3653-TPS3653	2.2	
209	Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3553-3553	2.2	1
208	Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 94-106	4.7	15
207	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 479-e899	5.7	23
206	Qualities and characteristics of applicants associated with successful matriculation to pediatric surgery fellowship training. <i>Journal of Pediatric Surgery</i> , <b>2020</b> , 55, 2075-2079	2.6	3
205	Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 88-94	4.9	3
204	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , <b>2020</b> , 126, 4936-4947	6.4	11
203	Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6112-6121	12.9	8
202	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3672-3684	2.2	37

201	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 828-836	12.9	18
200	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 581801	5.3	4
199	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , <b>2019</b> , 14, e0212097	3.7	4
198	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 9008-9013	11.5	67
197	Evaluation of confocal endoscopic microscopy for detection of early-stage gastric cancer in hereditary diffuse gastric cancer (HDGC) syndrome. <i>Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 10, 407-418	2.8	9
196	Survey of Surgical Oncology Fellowship Graduates 2005-2016: Insight into Initial Practice. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 1622-1628	3.1	5
195	Tumor grade and sex should influence the utilization of portal lymphadenectomy for early stage intrahepatic cholangiocarcinoma. <i>Hpb</i> , <b>2019</b> , 21, 419-424	3.8	6
194	Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 76-84	4.4	7
193	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2019</b> , 8, 247-257	4.4	8
192	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e349-e360	3.8	17
191	Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1447-1457	8.9	67
190	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6302-6308	12.9	6
189	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. <i>Blood</i> , <b>2019</b> , 134, 1536-1536	2.2	1
188	Phase 1b Study of Vopor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. <i>Blood</i> , <b>2019</b> , 134, 2867-2867	2.2	3
187	Infectious Complications Associated with CAR T-Cell Therapy. <i>Blood</i> , <b>2019</b> , 134, 4449-4449	2.2	6
186	Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2639-2639	2.2	3
185	Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7003-7003	2.2	4
184	Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivolpi).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4555-4555	2.2	

183	Prognostic value of sequential 18F-FDG + Na18F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivolpi).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4544-4544	2.2	
182	Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR. <i>Blood</i> , <b>2019</b> , 134, 4080-4080	2.2	
181	Stage and disease-free interval help select patients for surgical management of locally recurrent and metastatic adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 121, 228	2.8	2
180	Viral, immunologic, and clinical features of primary effusion lymphoma. <i>Blood</i> , <b>2019</b> , 133, 1753-1761	2.2	46
179	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , <b>2019</b> , 69, 2048-2060	11.2	41
178	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 207-215	21.7	111
177	Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods. <i>Academic Radiology</i> , <b>2018</b> , 25, 144-152	4.3	9
176	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2859-2872	12.9	25
175	MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 505-508	1.9	10
174	Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. <i>BMC Gastroenterology</i> , <b>2018</b> , 18, 94	3	3
173	A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 196	8.5	11
172	End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. <i>Haematologica</i> , <b>2018</b> , 103, 1337-1344	6.6	46
171	Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 147-147	2.2	10
170	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 753-765	12.9	16
169	Host-related immunodeficiency in the development of multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1127-1132	1.9	11
168	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations <b>2018</b> , 6, 141		132
167	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> , <b>2018</b> , 5, e609-e617	14.6	96
166	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer <b>2018</b> , 6, 91		40

165	An Examination of Applicants and Factors Associated with Matriculation to Complex General Surgical Oncology Fellowship Training Programs. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3436-3442	3.1	14
164	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 77-85	3.3	33
163	Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials. <i>American Journal of Roentgenology</i> , <b>2017</b> , 208, W31-W37	5.4	8
162	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4633-4641	12.9	56
161	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , <b>2017</b> , 22, 505-514	3.7	14
160	Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E162-E164	7.1	2
159	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell</i> , <b>2017</b> , 31, 833-843	15.279	4
158	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer <b>2017</b> , 5, 93		41
157	Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. <i>Translational Lung Cancer Research</i> , <b>2017</b> , 6, 588-599	4.4	5
156	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 289-297	1	33
155	Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1980-1988	4.7	4
154	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. <i>Surgery</i> , <b>2017</b> , 161, 230-239	3.6	43
153	Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26273	3	8
152	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 545-551	13.4	407
151	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 35-42	12.9	24
150	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 639-645	1.9	8
149	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , <b>2017</b> , 1, 1911-1918	7.8	31
148	Outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 10540-10540	2.2	0



147	A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoipi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4562-4562	2.2	14
146	Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5026-5026	2.2	8
145	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15786-e15786	2.2	7
144	Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20545-e20545	2.2	2
143	A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoipi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 293-293	2.2	12
142	Tremelimumab: A monoclonal antibody against CTLA-4 in combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 88-88 <sup>2-2</sup>		
141	A phase I dose expansion cohort study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2585-2585	2.2	
140	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 310-8	12.9	42
139	Malignant Mesothelioma Effusions Are Infiltrated by CD3 T Cells Highly Expressing PD-L1 and the PD-L1 Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1993-2005	8.9	77
138	Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1979-1986	2.6	2
137	Thoracic Surgery in Chronic Granulomatous Disease: a 25-Year Single-Institution Experience. <i>Journal of Clinical Immunology</i> , <b>2016</b> , 36, 677-83	5.7	5
136	Mutations in Latinos From the United States and Latin America. <i>Journal of Global Oncology</i> , <b>2016</b> , 2, 259-267		8
135	Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1616-24	1.9	9
134	Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumors. <i>American Journal of Surgery</i> , <b>2016</b> , 212, 40-6	2.7	3
133	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 235-51	4.4	14
132	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3182-91	12.9	67
131	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 730-738	11.6	93
130	Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. <i>Surgery</i> , <b>2016</b> , 159, 311-8	3.6	68

129	A phase II trial of vandetanib (ZD6474) in children and adults with wild-type gastrointestinal stromal tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11009-11009	2.2	3
128	SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11053-11053	2.2	16
127	Samarium-153-EDTMP (Quadramet <sup>®</sup> ) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , <b>2016</b> , 7, 69014-69023	3.3	31
126	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 461-73	2.9	26
125	Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. <i>Haematologica</i> , <b>2016</b> , 101, e27-9	6.6	17
124	Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1517-1524	4.7	9
123	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , <b>2016</b> , 101, 104-110	5.9	13
122	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4125-4131	2.2	57
121	Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1083-90	4.7	39
120	High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4312-20	12.9	6
119	EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. <i>Blood</i> , <b>2015</b> , 126, 863-72	2.2	178
118	Long-Term Outcome of Bilateral Laparoscopic Adrenalectomy Measured by Disease-Specific Questionnaire in a Unique Group of Patients with Cushing's Syndrome. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22 Suppl 3, S699-706	3.1	10
117	Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer. <i>European Journal of Radiology</i> , <b>2015</b> , 84, 1708-14	4.7	9
116	<sup>18</sup> F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 1250-60	7	24
115	Impact of telomere length on survival in classic and variant hairy cell leukemia. <i>Leukemia Research</i> , <b>2015</b> , 39, 1360-6	2.7	8
114	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1429-35	7.4	2
113	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , <b>2015</b> , 2, 39-50	4	9
112	Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 1096-102	5.1	13

111	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , <b>2015</b> , 385, 517-528	4.0	1926
110	ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans. <i>Blood</i> , <b>2015</b> , 126, 2291-301	2.2	11
109	Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. <i>Haematologica</i> , <b>2015</b> , 100, 1228-36	6.6	16
108	Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 23-32	5.1	25
107	Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. <i>BMJ Open</i> , <b>2015</b> , 5, e008248	3	22
106	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 746-54	13.4	224
105	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2015</b> , 1, 1087-95	13.4	58
104	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 177-86	21.7	160
103	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. <i>Blood</i> , <b>2015</b> , 126, 342-342	2.2	11
102	Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial. <i>Blood</i> , <b>2015</b> , 126, 65-65	2.2	1
101	The outcome of ALK positive and ALK negative anaplastic large cell lymphoma (ALCL) following DA-EPOCH.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8564-8564	2.2	1
100	Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 235-235	2.2	1
99	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. <i>Oncotarget</i> , <b>2015</b> , 6, 11694-703	3.3	47
98	EGFR mutations in Latinos from the United States and Latin America.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8070-8070	2.2	
97	Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis. <i>Blood</i> , <b>2015</b> , 126, 1937-1937	2.2	
96	Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1033-9	4.7	16
95	Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2727-39	12.9	47
94	Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. <i>Journal of Pediatrics</i> , <b>2014</b> , 164, 620-4	3.6	20

93	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 191-200	21.7	83
92	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 637-44	2.8	41
91	Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. <i>Blood</i> , <b>2014</b> , 124, 3544-52	2.2	67
90	A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5392-402	12.9	71
89	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4501-4501	2.2	21
88	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. <i>Oncotarget</i> , <b>2014</b> , 5, 8161-72	3.3	26
87	Systemic chemotherapy for the treatment of advanced biliary tract carcinoma (BTC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15129-e15129	2.2	
86	A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. <i>Molecular and Clinical Oncology</i> , <b>2013</b> , 1, 565-569	1.6	22
85	Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd IR) In High Risk Smoldering Multiple Myeloma Patients. <i>Blood</i> , <b>2013</b> , 122, 1939-1939	2.2	6
84	Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy. <i>Blood</i> , <b>2013</b> , 122, 3029-3029	2.2	7
83	Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , <b>2013</b> , 122, 538-538	2.2	29
82	Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd). <i>Blood</i> , <b>2013</b> , 122, 762-762	2.2	3
81	SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 10522-10522	2.2	17
80	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 10588-10588	2.2	2
79	CUSTOM (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies trial): A radical redesign of clinical trial structure Use of mass customization and product postponement.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6524-6524	2.2	1
78	Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8026-8026	2.2	16
77	A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4589-TPS4589	2.2	2
76	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 102-102	2.2	13

75	Effect of the addition of platinum to gemcitabine on outcome in patients with advanced pancreatic cancer who progress on gemcitabine: A comprehensive analysis of published trials.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 275-275	2.2	
74	Phase I/II study of the safety, pharmacokinetics, and efficacy of pomalidomide in the treatment of Kaposi sarcoma in individuals with or without HIV.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS10595-TPS10595		
73	Biologic variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: Multiple biopsies in the same patient.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e19506-e19506	2.2	
72	Chronic Graft-Versus-Host Disease (cGVHD) Patients with Bronchiolitis Obliterans Syndrome (BOS) Have Worse Clinical Manifestations and Severity of cGVHD with More Impairment in Self-Assessed Physical and Mental Health than cGVHD Patients without BOS. <i>Blood</i> , <b>2012</b> , 120, 1939-1939	2.2	2
71	Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , <b>2012</b> , 120, 3054-3054	2.2	1
70	Bortezomib + DA-EPOCH-R Induction Therapy Followed by Maintenance Bortezomib Versus Observation in Newly Diagnosed Mantle Cell Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 3672-3672	2.2	7
69	A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 3709-3709	2.2	1
68	Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , <b>2012</b> , 120, 732-732	2.2	3
67	Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2528-2528 <sup>2</sup>	2.2	2
66	Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4569-4569	2.2	3
65	Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e18568-e18568 <sup>2</sup>	2.2	3
64	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 207-207 <sup>2,2</sup>	2.2	5
63	Vaccine therapy with tumor-specific mutated ras peptides and IL-2, GM-CSF, or both in adult patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2577-2577	2.2	
62	A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3043-3043	2.2	
61	Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8051-8051	2.2	
60	Clinical, Immunologic, and Virologic Findings in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Lymphomas Suggest KSHV-Associated Inflammatory Syndromes Contribute to Symptoms and Disease Pathogenesis.. <i>Blood</i> , <b>2012</b> , 120, 2708-2708	2.2	
59	Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2012</b> , 120, 4206-4206	2.2	
58	Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT. <i>Blood</i> , <b>2012</b> , 120, 471-471	2.2	

57	Minor Histocompatibility Antigen Mismatch and Incidence of Graft Versus Host Disease, Event-Free, and Overall Survival in Patients Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2012</b> , 120, 4201-4201	2.2	
56	Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism. <i>Blood</i> , <b>2011</b> , 118, 1937-1937	2.2	
55	An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castlemans disease. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 350-8	11.6	189
54	Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.. <i>Blood</i> , <b>2010</b> , 112, 1845-1845	2.2	1
53	Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors. <i>Blood</i> , <b>2010</b> , 116, 3530-3530	2.2	
52	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , <b>2008</b> , 112, 2010-2010	2.2	1
51	Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.. <i>Blood</i> , <b>2007</b> , 110, 167-167	2.2	0
50	Early Results of a Clinical Trial Using Targeted Oncolytic Virotherapy in Kaposi Sarcoma Herpes Virus (KSHV) Associated Multicentric Castlemans Disease (MCD).. <i>Blood</i> , <b>2007</b> , 110, 514-514	2.2	1
49	Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.. <i>Blood</i> , <b>2007</b> , 110, 1064-1064	2.2	1
48	Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , <b>2006</b> , 108, 2871-2871	2.2	
47	Early selection in a randomized phase II clinical trial. <i>Statistics in Medicine</i> , <b>2002</b> , 21, 1711-26	2.3	39
46	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma <b>2002</b> , 94, 2333		1
45	Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. <i>Annals of Surgical Oncology</i> , <b>2001</b> , 8, 771-8	3.1	36
44	Polymorphisms in inflammatory cytokines and Fc gamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. <i>British Journal of Haematology</i> , <b>2001</b> , 113, 596-9	4.5	68
43	Biomarker assays in nipple aspirate fluid. <i>Breast Journal</i> , <b>2001</b> , 7, 378-87	1.2	33
42	Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look. <i>Cancer</i> , <b>2001</b> , 93, 409-14	6.4	9
41	Comparison of antibodies to MART-1 and MelanA in fine-needle aspiration samples of metastatic malignant melanoma. <i>Diagnostic Cytopathology</i> , <b>2001</b> , 25, 78-9	1.4	8
40	Clinical trial designs for the early clinical development of therapeutic cancer vaccines. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1848-54	2.2	98

39	Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 584-92	2.2	127
38	Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3477-82	2.2	272
37	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. <i>International Journal of Cancer</i> , <b>2000</b> , 86, 818-26	7.5	50
36	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. <i>Cancer Immunology, Immunotherapy</i> , <b>2000</b> , 49, 517-29	7.4	68
35	Activity of thalidomide in AIDS-related Kaposi's sarcoma. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2593-602.	2.2	261
34	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes <b>2000</b> , 86, 818		3
33	Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 968-75	2.2	267
32	Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>1998</b> , 26, 673-87		7
31	Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. <i>Cancer</i> , <b>1998</b> , 83, 1980-1988	6.4	11
30	Bronchiolization of the alveoli in lung cancer: pathology, patterns of differentiation and oncogene expression. <i>International Journal of Cancer</i> , <b>1998</b> , 75, 489-96	7.5	23
29	Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. <i>International Journal of Cancer</i> , <b>1998</b> , 75, 517-24	7.5	133
28	Response during radiotherapy may be associated with outcome in mediastinal Hodgkin's disease. <i>Radiation Oncology Investigations</i> , <b>1998</b> , 6, 216-25		3
27	Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. <i>Annals of Surgical Oncology</i> , <b>1998</b> , 5, 150-8	3.1	37
26	A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. <i>Pediatrics</i> , <b>1998</b> , 101, 335-43	7.4	92
25	Effect of L-Carnitine on Human Immunodeficiency Virus-1 Infection-Associated Apoptosis: A Pilot Study. <i>Blood</i> , <b>1998</b> , 91, 3817-3824	2.2	52
24	A phase I/II study of the protease inhibitor indinavir in children with HIV infection. <i>Pediatrics</i> , <b>1998</b> , 102, 101-9	7.4	68
23	Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer <b>1998</b> , 83, 1980		2
22	Simian virus-40 large-T antigen binds p53 in human mesotheliomas. <i>Nature Medicine</i> , <b>1997</b> , 3, 908-12	50.5	220

21	Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. <i>Annals of Surgical Oncology</i> , <b>1997</b> , 4, 628-33	3.1	179
20	Surgically debulked malignant pleural mesothelioma: results and prognostic factors. <i>Annals of Surgical Oncology</i> , <b>1997</b> , 4, 215-22	3.1	142
19	Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. <i>Cancer Investigation</i> , <b>1996</b> , 14, 513-7	2.1	43
18	Parental Expressed Needs. <i>Journal of HIV/AIDS Prevention and Education for Adolescents and Children</i> , <b>1996</b> , 1, 35-52		2
17	MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , <b>1996</b> , 24, 210-7	4.7	54
16	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. <i>Cancer</i> , <b>1996</b> , 78, 901-11	6.4	107
15	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors <b>1996</b> , 78, 901		3
14	Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. <i>Journal of Infectious Diseases</i> , <b>1995</b> , 171, 1152-8	7	40
13	A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1995</b> , 35, 457-63	3.5	23
12	Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. <i>Cancer</i> , <b>1995</b> , 75, 423-9	6.4	146
11	Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. <i>Cancer</i> , <b>1994</b> , 73, 1731-7	6.4	186
10	Clara cell 10 kDa protein mRNA in normal and atypical regions of human respiratory epithelium. <i>International Journal of Cancer</i> , <b>1994</b> , 58, 629-37	7.5	32
9	Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response <b>1994</b> , 73, 1731		1
8	A phase II evaluation of thiotepa in pediatric central nervous system malignancies. <i>Cancer</i> , <b>1993</b> , 72, 2716-4	6.4	52
7	Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome. <i>Cancer</i> , <b>1993</b> , 72, 726-34	6.4	23
6	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. <i>Journal of Surgical Oncology</i> , <b>1993</b> , 53, 252-5	2.8	3
5	Correlative detection of human immunodeficiency virus (HIV) antigen p24 and Epstein-Barr virus DNA in vitro: clinical influence on HIV infection. <i>Microbiology and Immunology</i> , <b>1992</b> , 36, 905-9	2.7	1
4	Analysis of iodine-125 interstitial therapy in the treatment of localized carcinoma of the prostate. <i>Journal of Surgical Oncology</i> , <b>1991</b> , 46, 235-40	2.8	4



3	Determinants of survival in patients with unresectable colorectal liver metastases. <i>Journal of Surgical Oncology</i> , <b>1989</b> , 40, 245-51	2.8	34
2	Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. <i>Journal of Surgical Oncology</i> , <b>1989</b> , 41, 263-73	2.8	54
1	Computerized tomographic prediction of extraluminal spread and prognostic implications of lesion width in esophageal carcinoma. <i>Cancer</i> , <b>1988</b> , 62, 1287-92	6.4	26